Response to Yilmaz et al.-Reference-Cited by-同舟云学术

Response to Yilmaz et al.

Published:2024-04-03 Issue:5 Volume:35 Page:481-482
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Cabezas-Camarero Santiago¹,Iglesias-Moreno María Cruz²,Cerezo Druet Elena³,Sotelo Miguel J.⁴⁵⁶,Merino-Menéndez Salomé⁷,Cabrera-Martín María Nieves⁸,Plaza-Hernández José Carlos⁹,Pérez-Segura Pedro¹

Affiliation:

1. Medical Oncology Department, Instituto de Investigación Sanitaria San Carlos (IdISSC)

2. Department of Otolaryngology-Head and Neck Surgery, Instituto de Investigación Sanitaria San Carlos (IdISSC)

3. Radiation Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain

4. Medical Oncology Department, Aliada Cancer Center, Lima, Perú

5. Medical Oncology Department, Clínica San Felipe, Lima, Perú

6. Medical Oncology Department, Hospital María Auxiliadora, Lima, Perú

7. Radiology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain

8. Nuclear Medicine Department, Hospital Clínico Universitario San Carlos, Hospital Clínico Universitario San Carlos, Madrid, Spain

9. Pathology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference14 articles.

1. In regard to Cabezas-Camarero et al.;Yilmaz;Anticancer Drugs,2023

2. Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: a single-center experience.;Sari;Oral Oncol,2022

3. The synergistic effect of immune checkpoint blockade and radiotherapy in recurrent/metastatic sinonasal cancer.;Yazici;Cureus,2018

4. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.;Tao;Ann Oncol,2023

5. Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: the safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).;Tao;Eur J Cancer,2020